CURI
CuriosityStream Inc.
CURI has lower modeled downside risk, despite its lower overall score.
RDDT
Reddit, Inc.
RDDT has the edge over CURI overall, supported by stronger fundamentals and stronger modeled upside.
CURI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CURI's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RDDT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
RDDT's revenue, profitability, cash flow and balance sheet are all currently healthy.
CURI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $2.86 | — |
| Current | 20x | $2.86 | — |
| Cheap | N/A | N/A | N/A |
| Fair | N/A | N/A | N/A |
| Expensive | N/A | N/A | N/A |
Historical ranges are pointers, not guarantees.
CURI has the edge over RDDT in the historical PE scenario, which offers more potential upside but is not a forecast.
RDDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $99.55 | — |
| Current | 20x | $99.55 | — |
| Cheap | 35x | $171 | +72% |
| Fair | 46x | $228 | +129% |
| Expensive | 53x | $262 | +163% |
Historical ranges are pointers, not guarantees.
RDDT's PE is 20x, but its earnings don't support one, so it isn't a reliable read right now.
CURI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CURI, with profitability improving. However, they disagree widely on these estimates.
RDDT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect strong earnings and revenue growth for RDDT, with profitability improving. However, they disagree widely on these estimates.
CURI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.24 | +75% |
| Q3 2026 | $0.14 | +$0.23 |
| Q2 2026 | $0.00 | +$0.09 |
| Q1 2026 | -$0.14 | $0.00 |
| Q4 2025 | -$0.11 | +$0.13 |
| Q3 2025 | -$0.09 | +$0.18 |
| Q2 2025 | -$0.09 | +$0.62 |
| Q1 2025 | -$0.14 | +$0.72 |
| Q4 2024 | -$0.24 | +$0.68 |
CURI has the stronger earnings trend. Trailing diluted EPS is up 56% for CURI versus RDDT down 39%.
RDDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.32 | +29% |
| Q3 2024 | -$7.98 | -$7.17 |
| Q2 2024 | -$8.19 | -$7.15 |
| Q1 2024 | -$8.38 | -$7.25 |
| Q4 2023 | -$0.56 | +$0.41 |
| Q3 2023 | -$0.81 | -$0.02 |
| Q2 2023 | -$1.04 | -$0.48 |
| Q1 2023 | -$1.13 | -$0.48 |
| Q4 2022 | -$0.97 | -$0.19 |
RDDT has returned to profit: it earned $4.90 per share over the past year, after losing money the year before.
CURI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7M | +13% |
| Q2 2026 | $23.2M | +22% |
| Q1 2026 | $15.2M | +0.5% |
| Q4 2025 | $19.2M | +36% |
| Q3 2025 | $18.4M | +46% |
| Q2 2025 | $19M | +53% |
| Q1 2025 | $15.1M | +26% |
| Q4 2024 | $14.1M | -4.3% |
CURI's revenue is recovering but still below its 2021 peak: $21M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +42 points |
| Q2 2026 | 39% | +37 points |
| Q1 2026 | -10% | -11 points |
| Q4 2025 | -18% | +9.9 points |
| Q3 2025 | -24% | +1.3 points |
| Q2 2025 | 2.5% | +23 points |
| Q1 2025 | 0.5% | +31 points |
| Q4 2024 | -27% | +4.8 points |
CURI's operating margin was 18% last quarter, up 42 points from the same quarter a year ago, near the top of its range since 2019.
RDDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $895M | +53% |
| Q2 2026 | $804.9M | +61% |
| Q1 2026 | $663.4M | +69% |
| Q4 2025 | $725.6M | +70% |
| Q3 2025 | $584.9M | +68% |
| Q2 2025 | $499.6M | +78% |
| Q1 2025 | $392.4M | +61% |
| Q4 2024 | $427.7M | +71% |
RDDT has the edge over CURI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 29% | +5.5 points |
| Q2 2026 | 29% | +15 points |
| Q1 2026 | 28% | +27 points |
| Q4 2025 | 32% | +20 points |
| Q3 2025 | 24% | +22 points |
| Q2 2025 | 14% | +25 points |
| Q1 2025 | 1% | +244 points |
| Q4 2024 | 12% | +11 points |
RDDT has the edge over CURI on profitability, with a higher operating margin.
CURI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.4M | +0.5% |
| Q2 2026 | -$4.2M | -249% |
| Q1 2026 | $1.2M | -34% |
| Q4 2025 | $3.9M | +30% |
| Q3 2025 | $4.4M | +94% |
| Q2 2025 | $2.8M | +27% |
| Q1 2025 | $1.8M | +177% |
| Q4 2024 | $3M | +$5.6M |
CURI has burned cash in most quarters: $5M over the past year, down 55% from the year before.
RDDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $362.6M | +98% |
| Q2 2026 | $260.7M | +135% |
| Q1 2026 | $311.2M | +146% |
| Q4 2025 | $263.6M | +196% |
| Q3 2025 | $183.1M | +161% |
| Q2 2025 | $110.8M | +308% |
| Q1 2025 | $126.6M | +333% |
| Q4 2024 | $89.2M | +$111.2M |
RDDT has the edge over CURI on cash flow, with more consistent year-over-year improvement.
CURI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -164K shares |
| 1 year | +4.3% | +2.5M shares |
| 3 years | +14% | +7.4M shares |
| 5 years | +26% | +12.4M shares |
| Available history | +264% | +43.9M shares |
CURI has 60M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $560,000 |
| Q1 2026 | $311,000 |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $33,000 |
| Q3 2024 | $192,000 |
| Q4 2020 | — |
CURI spent $871,000 buying back its own shares over the past year.
RDDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -169K shares |
| 1 year | -0.4% | -868K shares |
| 3 years | +24% | +38.5M shares |
| 5 years | +24% | +38.5M shares |
RDDT has the edge over CURI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100.4M |
| Q2 2026 | $234.6M |
| Q1 2026 | $5M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $4.2M |
| Q4 2022 | — |
CURI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
CURI has more cash than debt.
RDDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.9x | Net Cash |
| Q1 2026 | -2.2x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -3.3x | Net Cash |
| Q2 2025 | -5.0x | Net Cash |
| Q1 2025 | -13.1x | Net Cash |
RDDT has the edge over CURI on leverage, with a lower net debt burden relative to earnings.
CURI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.2 | Neutral |
| Stochastic | 14.3 | Oversold |
CURI's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
RDDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 6.5 | Oversold |
RDDT's weekly RSI is 35 (neutral) and its Stochastic is 6 (oversold).
CURI PE vs Communication Services Sector
RDDT PE vs Communication Services Sector
| Metric | RDDT | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 16x | 23% above |
| PE % | 5 | 23 | 18 pts below |
RDDT is trading at 20x earnings, a 23% premium to the Communication Services sector's median of 16x, though its earnings don't support one.
CURI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.78 | 2.9% above |
| 20 week MA | $2.75 | 4% above |
| 50 week MA | $3.07 | 6.8% below |
| 100 week MA | $3.49 | 18% below |
| 200 week MA | $2.31 | 24% above |
CURI has stronger trend alignment. CURI is above 3 of 5 weekly averages versus RDDT above 0 of 4.
RDDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $130.6 | 24% below |
| 20 week MA | $151.7 | 34% below |
| 50 week MA | $165.0 | 40% below |
| 100 week MA | $167.1 | 40% below |
RDDT is in a downtrend: it's below all four of its weekly moving averages, and 40% below its 100-week average.
CURI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.90 | $13.8 | +39% |
| 2021 | $13.8 | $6.44 | -53% |
| 2022 | $6.44 | $1.17 | -82% |
| 2023 | $1.17 | $0.54 | -54% |
| 2024 | $0.54 | $1.58 | +193% |
| 2025 | $1.58 | $3.83 | +142% |
| 2026 YTD | $3.83 | $2.86 | -25% |
CURI has the edge over RDDT on returns for 2026, with the stronger performance.
RDDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $46.0 | $173.5 | +277% |
| 2025 | $173.5 | $225.8 | +30% |
| 2026 YTD | $225.8 | $99.6 | -56% |
RDDT has finished every year since 2024 higher, and it's down 56% so far in 2026.